Home Ingredients Honokiol (Magnolia officinalis Bark)
Stress & AnxietySleep HealthMood & Mental HealthAnti-Inflammatory

Honokiol (Magnolia officinalis Bark)

Magnolia officinalis Rehder & E.H. Wilson (Hou Po)
Evidence Level
Limited
3 Clinical Trials
8 Documented Benefits
2/5 Evidence Score

A bi-phenolic natural product from the bark and seed cones of Magnolia officinalis — used in TCM for over two millennia as 'hou po' (厚朴) to 'regulate Qi'. Positional isomer of magnolol; both compounds typically present in magnolia bark extracts in varying ratios. Acts as a positive allosteric modulator of GABA-A receptors at both synaptic and extra-synaptic sites — distinct from the benzodiazepine binding site (Alexeev et al., PMC3652012). Kalman 2008 (Relora® 6-week RCT in premenopausal women) and Mucci 2006 small clinical studies showed reduced anxiety and improved sleep. Strong preclinical anti-cancer evidence across multiple tumor types — but human cancer trials are absent, an important honest counter-evidence to enthusiastic anti-cancer marketing. Mouse kidney toxicology study warrants caution at higher doses.

Studied Dose PURIFIED HONOKIOL: 250 mg 1-2×/day. RELORA® (Magnolia + Phellodendron): 250-300 mg 2-3×/day. Kalman 2008 6-week RCT premenopausal women dose. Pregnancy: avoid. Avoid combining with benzodiazepines or alcohol. Mouse toxicology suggests caution at high doses or extended use.
Active Compound Honokiol (3',5-di-2-propenyl-1,1'-biphenyl-2,4'-diol) — bi-phenolic compound. Magnolol is positional isomer (5,5'-diallyl-2,2'-dihydroxybiphenyl). Both compounds typically present in magnolia bark extracts

Benefits

Anxiety reduction premenopausal women (Relora® 6-week RCT)

PMC2359758 Kalman 2008 — randomized parallel placebo-controlled 6-week trial in healthy overweight premenopausal women using Relora® 250 mg capsules three times daily. Anxiety reduction measured via Spielberger State-Trait inventory plus salivary amylase and cortisol. Sleep quality and latency improved per Likert/VAS measures. Note: this is a Magnolia + Phellodendron combination product, not purified honokiol.

Supported by Trial 1

Anxiety + sleep reduction (Mucci 2006 + Kalman 2008)

Aggregate small clinical evidence: Mucci 2006 plus Kalman 2008 — two clinical studies finding magnolia extracts reduce temporary anxiety and improve sleep. Preliminary clinical signal that motivates continued research interest, though dedicated large-scale honokiol-specific trials are lacking.

Supported by Trial 3

Cortisol and DHEA modulation (Relora® preliminary)

Preliminary Relora unpublished data: morning cortisol effects plus DHEA elevation. Mechanistic alignment with the HPA-axis modulation hypothesis. Unpublished data — interpretation cautious pending peer review.

Supported by Trial 1

Stress-related body weight changes

Stress-related body weight changes published separately from primary Kalman 2008 anxiety endpoints. Suggests a specific population (stress-related eating in women) where Relora® may be most relevant.

Supported by Trial 1, Trial 3

GABA-A receptor positive allosteric modulation (foundational pharmacology)

Alexeev et al. (PMC3652012, Neuropharmacology) characterized magnolol AND honokiol as positive allosteric modulators of both synaptic and extra-synaptic GABA-A receptors. Mechanism is distinct from the benzodiazepine binding site, with subunit heterogeneity sensitivity. The pharmacological basis for the anxiolytic and sleep effects.

Supported by Trial 2

Anti-cancer preclinical evidence (multiple cancer types)

Extensive preclinical anti-cancer evidence across lung, breast, prostate, leukemia, melanoma, glioblastoma, neuroblastoma, oral, bladder, and colorectal cancer cell lines and mouse models — antitumor and antiangiogenic effects. Honest counter-evidence: NO human cancer clinical trials registered. Three NIH-funded preclinical projects active (lung, breast, kidney). 20+ years of preclinical research interest has not translated to human trials — important reality check on enthusiastic anti-cancer marketing claims.

Supported by Trial 1

Neuroprotective preclinical (Alzheimer's, Parkinson's)

Lee et al. neuroprotective Alzheimer's mouse model evidence (LPS-induced and Aβ oligomer-induced neuronal damage). Antioxidant and anti-apoptotic mechanisms in neuronal cell models. Preclinical only — human translation not demonstrated.

Anti-inflammatory effects (preclinical)

TNF-α and IL-8 reduction in THP-1 cells and other anti-inflammatory signals across preclinical models. Mechanistic complement to the GABAergic and HPA-axis effects.

Supported by Trial 1

Mechanism of action

1

GABA-A receptor positive allosteric modulation (synaptic + extra-synaptic)

Alexeev et al. PMC3652012 characterized magnolol and honokiol as positive allosteric modulators of both synaptic and extra-synaptic GABA-A receptors. Mechanism is distinct from the benzodiazepine binding site, with subunit heterogeneity sensitivity. Both fast inhibitory neurotransmission (synaptic) and tonic inhibition (extra-synaptic) are modulated — broader than typical benzodiazepine effects.

2

Cortisol / HPA axis modulation

Kalman 2008 reported salivary cortisol effects; preliminary Relora data shows morning cortisol modulation and DHEA elevation. HPA-axis stress response modulation complements the GABAergic mechanism.

3

Anti-inflammatory NF-κB pathway

Honokiol suppresses NF-κB signaling and reduces inflammatory cytokines (TNF-α, IL-8) — broad anti-inflammatory mechanism shared with many natural-product compounds.

4

Antioxidant + anti-apoptotic neuronal protection (preclinical)

Multi-mechanism preclinical neuroprotection: antioxidant activity plus anti-apoptotic effects in neuronal cell models, including Alzheimer's mouse models. Mechanistic basis for the neuroprotective research interest.

5

Anti-cancer multi-pathway preclinical

Multiple preclinical anti-cancer pathways: angiogenesis inhibition, apoptosis induction, cell cycle arrest, multi-pathway signaling effects across cancer types. Promising in vitro and animal-model activity that has not yet translated to human cancer trials.

6

Antimicrobial activity

Honokiol shows antimicrobial activity in vitro against various pathogens. Auxiliary mechanism beyond the central GABAergic and HPA-axis effects.

Clinical trials

1
Kalman 2008 — Relora® Anxiety + Sleep RCT (PMC2359758, PIVOTAL)

PMC2359758 Kalman 2008 — randomized parallel placebo-controlled 6-week trial in healthy overweight premenopausal women using Relora® 250 mg capsules three times daily. Anxiety reduction via Spielberger State-Trait inventory plus salivary amylase and cortisol; sleep quality and latency improved per Likert/VAS. Combination product (Magnolia officinalis + Phellodendron amurense) — not purified honokiol.

2
Alexeev — Magnolol + Honokiol GABA-A Mechanism Characterization (PMC3652012)

Alexeev et al. (PMC3652012, Neuropharmacology) — characterized magnolol and honokiol as positive allosteric modulators of both synaptic and extra-synaptic GABA-A receptors. Mechanism distinct from the benzodiazepine binding site; subunit heterogeneity sensitivity. Foundational pharmacology paper supporting the anxiolytic and sleep clinical findings.

3
Mucci 2006 + Kalman 2008 — Magnolia Anxiety/Sleep Aggregate

Two clinical studies (Mucci 2006 and Kalman 2008) finding magnolia extracts reduce temporary anxiety and improve sleep. Aggregate small-trial clinical signal supporting the mild anxiety/sleep adjunct positioning.

Side effects and drug interactions

Common Potential side effects

Generally well-tolerated at typical doses.
GI upset (rare).
Heartburn, trembling hands, sexual dysfunction, thyroid dysfunction reported in 4 patients across Relora studies (n=58 postmenopausal women, 6 weeks) — causality unclear (honokiol vs berberine vs combination).
TOXICOLOGY CONCERN: methanol extract of M. officinalis (2 mg/day honokiol equivalent for 3 MONTHS in mice) showed CHANGES IN KIDNEY FUNCTION CLINICAL PARAMETERS + KIDNEY ULTRASTRUCTURE ALTERATIONS. Clinical translation uncertain. Other animal toxicology studies have not reported significant safety concerns.
Pregnancy/lactation: AVOID (limited safety data).
VERY HIGH DOSES: theoretical hepatotoxicity, GI disturbances, neurotoxicity per limited evidence.
NO ongoing clinicaltrials.gov registered honokiol trials in the US — limited modern clinical safety data.
Long-term safety: limited human data beyond 6-week trials.

Important Drug interactions

Benzodiazepines: theoretical SYNERGISTIC effects (both GABA-A modulators, different sites) — caution.
Alcohol: theoretical additive sedation — avoid combination.
Anticoagulants: theoretical mild antiplatelet effect.
Antihypertensives: theoretical mild effects.
Most medications: caution due to limited modern PK/interaction data.
Other CNS depressants: theoretical additive sedation.

More Stress & Anxiety Ingredients

Muscle & Recovery
Magnesium
Magnesium is the fourth most abundant mineral in the body and a cofactor for over 300 enzy…
Cognitive
Ashwagandha
Ashwagandha is an adaptogenic herb that may reduce stress, enhance mood, and support overa…
Cognitive
KSM-66®
KSM-66 Ashwagandha, a standardized root extract, promotes stress relief and cognitive clar…
Cognitive
Phosphatidylserine
Phosphatidylserine (PS) is a phospholipid concentrated in neuronal cell membranes (10-20%…

Explore Other Ingredients

Sleep Health
Valerian Root
Valerian root is one of the most widely used herbal sleep aids in Western medicine, with a…
Cognitive
Rhodiola Rosea
Rhodiola rosea is an adaptogenic herb from arctic and mountainous regions of Europe and As…
Sleep Health
Serezin™
Serezin™ is PLT Health Solutions' patented blend of Boswellia serrata and ginger (Zingiber…

Frequently asked questions about Honokiol (Magnolia officinalis Bark)

What is the recommended dosage of Honokiol (Magnolia officinalis Bark)?

The clinically studied dose for Honokiol (Magnolia officinalis Bark) is PURIFIED HONOKIOL: 250 mg 1-2×/day. RELORA® (Magnolia + Phellodendron): 250-300 mg 2-3×/day. Kalman 2008 6-week RCT premenopausal women dose. Pregnancy: avoid. Avoid combining with benzodiazepines or alcohol. Mouse toxicology suggests caution at high doses or extended use.. Always follow product labeling and consult a healthcare provider for personalized dosing recommendations.

What is Honokiol (Magnolia officinalis Bark) used for?

Honokiol (Magnolia officinalis Bark) is studied for anxiety reduction premenopausal women (relora® 6-week rct), anxiety + sleep reduction (mucci 2006 + kalman 2008), cortisol and dhea modulation (relora® preliminary). PMC2359758 Kalman 2008 — randomized parallel placebo-controlled 6-week trial in healthy overweight premenopausal women using Relora® 250 mg capsules three times daily.

Are there side effects from taking Honokiol (Magnolia officinalis Bark)?

Reported potential side effects may include: Generally well-tolerated at typical doses. GI upset (rare). Always consult a healthcare provider before starting any new supplement, especially if you have underlying conditions or take medications.

Does Honokiol (Magnolia officinalis Bark) interact with medications?

Known drug interactions may include: Benzodiazepines: theoretical SYNERGISTIC effects (both GABA-A modulators, different sites) — caution. Alcohol: theoretical additive sedation — avoid combination. Consult a pharmacist or healthcare provider if you take prescription medications.

Is Honokiol (Magnolia officinalis Bark) good for stress & anxiety?

Yes, Honokiol (Magnolia officinalis Bark) is researched for Stress & Anxiety support. Stress-related body weight changes published separately from primary Kalman 2008 anxiety endpoints. Suggests a specific population (stress-related eating in women) where Relora® may be most relevant.